C08F220/603

DERIVATIZABLE MONOMERS AND POLYMERS, AND METHODS FOR MAKING AND USING SAME
20210388138 · 2021-12-16 ·

The invention provides UV-sensitive monomers, comprising a cyclopropenone-containing group, which acts as a masked dibenzocyclooctyne (DBCO)/dibenzoazocyclooctyne (DIBAC) group. The monomers of the invention can be polymerized for example via reversible addition fragmentation chain transfer (RAFT) polymerization techniques to yield a polymer comprising the masked DBCO/DIBAC group. In certain embodiments, the DBCO/DIBAC group can be unmasked under controlled conditions, allowing conjugation of small molecules and/or macromolecules to the polymer through highly selective and efficient strain-promoted azide alkyne click chemistry (SPAAC).

DERIVATIZABLE MONOMERS AND POLYMERS, AND METHODS FOR MAKING AND USING SAME
20210388138 · 2021-12-16 ·

The invention provides UV-sensitive monomers, comprising a cyclopropenone-containing group, which acts as a masked dibenzocyclooctyne (DBCO)/dibenzoazocyclooctyne (DIBAC) group. The monomers of the invention can be polymerized for example via reversible addition fragmentation chain transfer (RAFT) polymerization techniques to yield a polymer comprising the masked DBCO/DIBAC group. In certain embodiments, the DBCO/DIBAC group can be unmasked under controlled conditions, allowing conjugation of small molecules and/or macromolecules to the polymer through highly selective and efficient strain-promoted azide alkyne click chemistry (SPAAC).

IMIDAZOLIUM ZWITTERION POLYMERIZABLE COMPOUNDS AND OPHTHALMIC DEVICES INCORPORATING THEM
20210388141 · 2021-12-16 ·

Provided are imidazolium zwitterion polymerizable compounds and their applications in ophthalmic devices and packaging solutions. The zwitterionic polymerizable compounds are of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, and R.sub.g are as described herein.

IMIDAZOLIUM ZWITTERION POLYMERIZABLE COMPOUNDS AND OPHTHALMIC DEVICES INCORPORATING THEM
20210388141 · 2021-12-16 ·

Provided are imidazolium zwitterion polymerizable compounds and their applications in ophthalmic devices and packaging solutions. The zwitterionic polymerizable compounds are of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, and R.sub.g are as described herein.

Flow cells with chambers, depressions, and capture sites

An example of a flow cell includes a substrate, a plurality of chambers defined on or in the substrate, and a plurality of depressions defined in the substrate and within a perimeter of each of the plurality of chambers. The depressions are separated by interstitial regions. Primers are attached within each of the plurality of depressions, and a capture site is located within each of the plurality of chambers.

Flow cells with chambers, depressions, and capture sites

An example of a flow cell includes a substrate, a plurality of chambers defined on or in the substrate, and a plurality of depressions defined in the substrate and within a perimeter of each of the plurality of chambers. The depressions are separated by interstitial regions. Primers are attached within each of the plurality of depressions, and a capture site is located within each of the plurality of chambers.

Polymer of gamma-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal and its application in the field of drug delivery

This present invention relates to a polymer of γ-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal. The polymer comprises a γ-glutamyl transpeptidase-responsive element represented by Formula (I). When the polymer is used as drug carrier for anticancer drug, it can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field. ##STR00001##

Polymer of gamma-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal and its application in the field of drug delivery

This present invention relates to a polymer of γ-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal. The polymer comprises a γ-glutamyl transpeptidase-responsive element represented by Formula (I). When the polymer is used as drug carrier for anticancer drug, it can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field. ##STR00001##

HYDROGEL

A hydrogel includes a dendritic core with 2 to 30 arms, and first and second acrylamide monomers incorporated into each arm. The first acrylamide monomer is: (I), wherein R.sub.1 and R.sub.2 are independently selected from an alkyl, an alkylamino, an alkylamido, an alkylthio, an aryl, a glycol, and optionally substituted variants thereof; and the second acrylamide monomer is: (II), wherein R.sub.3 and R.sub.4 are independently hydrogen or an alkyl; L is a linker including a linear chain of 2 to 20 atoms selected from carbon, oxygen, and nitrogen and optional substituents on the carbon and any nitrogen atoms; A is an N substituted amide: (III), where R.sub.5 is hydrogen or an alkyl; E is a linear chain of 1 to 4 atom(s) selected from carbon, oxygen and nitrogen, and optional substituents on the carbon and any nitrogen atoms; and Z is an optional nitrogen containing heterocycle.

##STR00001##

HYDROGEL

A hydrogel includes a dendritic core with 2 to 30 arms, and first and second acrylamide monomers incorporated into each arm. The first acrylamide monomer is: (I), wherein R.sub.1 and R.sub.2 are independently selected from an alkyl, an alkylamino, an alkylamido, an alkylthio, an aryl, a glycol, and optionally substituted variants thereof; and the second acrylamide monomer is: (II), wherein R.sub.3 and R.sub.4 are independently hydrogen or an alkyl; L is a linker including a linear chain of 2 to 20 atoms selected from carbon, oxygen, and nitrogen and optional substituents on the carbon and any nitrogen atoms; A is an N substituted amide: (III), where R.sub.5 is hydrogen or an alkyl; E is a linear chain of 1 to 4 atom(s) selected from carbon, oxygen and nitrogen, and optional substituents on the carbon and any nitrogen atoms; and Z is an optional nitrogen containing heterocycle.

##STR00001##